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Background: Bovine neonatal pancytopenia (BNP) is a disease syndrome in newborn calves of up to four weeks of
age, first observed in southern Germany in 2006. By now, cases have been reported in several countries around the
globe. Many affected calves die within days due to multiple haemorrhages, thrombocytopenia, leukocytopenia and
bone marrow depletion. A certain vaccine directed against Bovine Virus Diarrhoea Virus (BVDV) was recently shown
to be associated with BNP pathogenesis. Immunized cows develop alloantibodies that are transferred to newborn
calves via colostrum intake. In order to further elucidate BNP pathogenesis, the purpose of this study was to
characterize and compare the protein composition of the associated vaccine to another vaccine directed against
BVDV not related to BNP and the cell surface proteome of MDBK (Madin-Darby Bovine Kidney) cells, the cell line
used for production of the associated vaccine.
Results: By SDS-PAGE and mass spectrometry, we were able to detect several coagulation-related and immune
modulatory proteins, as well as cellular and serum derived molecules being shared between the associated vaccine
and MDBK cells. Furthermore, the number of proteins identified in the BNP related vaccine was almost as high as
the number of surface proteins detected on MDBK cells and exceeded the amount of proteins identified in the
non-BNP related vaccine over 3.5 fold. The great amount of shared cellular and serum derived proteins confirm that
the BNP associated vaccine contained many molecules originating from MDBK cells and vaccine production.
Conclusions: The respective vaccine was not purified enough to prevent the development of alloantibodies. To
narrow down possible candidate proteins, those most likely to represent a trigger for BNP pathogenesis are
presented in this study, giving a fundament for further analysis in future research.Background
Bovine neonatal pancytopenia (BNP) is a disease trans-
ferred by colostral alloantibodies binding to peripheral
blood-derived leukocytes and platelet antigens of calves
[1]. Remarkably, calves develop a severe thrombocytopenia
and leukocytopenia within few hours after passive transfer
of colostral antibodies to blood and die within several days
from bleeding disorder and bone marrow depletion [1,2].
Respective alloantibodies responsible for BNP can develop
in cows previously vaccinated with a specific Bovine Viral
Diarrhoea (BVD) vaccine (PregSure BVD; Pfizer, Berlin,
Germany; vaccine A) [1]. Colostra of these cows transfer* Correspondence: Deeg@tiph.vetmed.uni-muenchen.de
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reproduction in any medium, provided the orBNP to healthy calves, indicating a commonly expressed
target antigen in responding calves [2]. Alloantibodies are
also detectable in blood of respective BNP dams [1], sug-
gesting their development to be systemically and not dir-
ectly in udder. Further immunological characterization of
these antibodies revealed that they were of IgG1 subclass
[3]. IgG1 antibodies reflect a Th2-response in cows. So far,
Major histocompatibility complex class I (MHC I) was
identified as one potential BNP alloantigen in two inde-
pendent studies, one demonstrating alloimmune reactions
to MDBK cell lysates of BNP donors [4] and the other
describing responses to vaccine A derived proteins [5], but
there are also other data indicating a different alloantigen
[3]. Defects in coagulation of platelets, the decline of plate-
lets and thus the low platelet count are the main cause for
the multiple haemorrhages leading to the death of affectedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 1D gel demonstrating diverging protein concentration
in BVD vaccines and MDBK cell lysate, silver stained. 50 μg of
PregSure BVD (vaccine B), the according volume Vacoviron FS
(vaccine A) and 50 μg MDBK cell lysate were loaded on a 10% SDS-
Gel, resolved by SDS-PAGE and silver stained. A: Molecular weight
marker. B: Vaccine B. C: Vaccine A. D: MDBK cell lysate.
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pressed on mature PBL as Assad et al. demonstrated bind-
ing of colostrum-derived antibodies to several PBL subsets
and platelets [3], and further on hematopoietic progenitor
cells of the myeloid and lymphoid lineages in the bone mar-
row, as these are, according to Laming et al., comprised
already 24 hours after colostrum intake and show a drastic
decline within the first 6 days after colostrum intake [6].
BNP dams clearly develop alloreactive responses after
vaccination with vaccine A, but not with other BVD vac-
cines [7,8]. Immunization of experimental calves and
guinea pigs with this vaccine led to generation of alloan-
tibodies [9], which were also cross-reactive with MDBK
cells [10], the cell line used for production of vaccine A
[9]. MDBK line was derived from the renal tissue of an
adult steer in 1957 [10]. MDBK cells are susceptible to
infection with BVDV and a number of other viruses,
including vesicular stomatitis virus, infectious bovine
rhinotracheitis virus, bovine parvovirus, bovine adeno-
virus I and III, and parainfluenza virus 3 [11]. MDBK
cells exhibit resistance to poliovirus 2 and are negative
for reverse transcriptase.
Therefore, the goal of this study was to characterize and
compare protein expression of MDBK cells, BNP associated
vaccine A, and - as negative control to contrast the BVD
virus associated constituents - a live-attenuated BVD vac-
cine unrelated to BNP (Vacoviron FS; Merial, Hallbergmoos,
Germany; vaccine B) by label free mass spectrometry. The
results may improve our understanding of differences in
vaccine composition that could account for alloantibody
formation in BNP dams.
Results
BNP associated BVD vaccine contains a variety of
different proteins
First evaluation of protein composition of different BVD
vaccines showed a clear difference between vaccine B
(Figure 1B) and A (Figure 1C). Vaccine A, related to BNP,
included many different proteins in comparison to vaccine
B which is not associated with BNP. Quantitative staining
with colloidal Coomassie demonstrated a remarkable dif-
ference in protein concentration of vaccine A compared
to vaccine B. In addition, silver staining confirmed little
protein content in vaccine B (Figure 1B) whereas vaccine
A (Figure 1C) resembled the composition of MDBK cell
proteome (Figure 1D).
We therefore decided to identify all proteins of respec-
tive samples with LC-MS/MS to categorize duplicate pro-
teins in vaccine A and MDBK cells.
Mass spectrometric classification of protein content confirms
large overlap between MDBK and PregSure BVD proteomes
A total of 310 proteins were identified by LC-MS/MS in
this study (see Additional file 1). 43 proteins were identifiedwith two or more peptides in vaccine B, a live-attenuated
vaccine which is not related to BNP. In contrast, 159 pro-
teins were detectable in vaccine A (vaccination with this
vaccine strongly correlates with BNP occurrence) and 163
proteins on MDBK cell surface of which 66% are allocated
to the Gene ontology (GO) project terms “plasma mem-
brane”, “cell surface” or “extracellular”. There was an over-
lap of eight proteins in all three samples analyzed. Eleven
proteins were present only in both vaccines A and B, but
not on MDBK cells. Three other proteins, alpha-S1-casein,
kappa-casein and keratin-5 appeared concurrently in
vaccine B and MDBK cells. Two BVD virus polypro-
tein peptides were detected in both vaccines (vaccine A:
EMBL Database Accession Number: ABP57735.1; EMBL
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Database Accession Number AAC61755.1).
Between vaccine A and MDBK cells, we detected 25
shared proteins (Tables 1 and 2). Among these were 17 pro-
teins representing cellular components (Table 1, proteins
1–12, 14, 15, 17, 18 and 25), e.g. histone H2B type 1 and
mitochondrial proteins ATP synthase subunits alpha, beta
and adenylate kinase 2 (AK 2). Further, we detected ribo-
somal proteins S3, S4 and L7a and representatives of cyto-
plasmatic protein fraction. The latter were structural
proteins of the cytoskeleton, such as actin, or proteins in
charge of energy balance like glyceraldehyde-3-phosphateTable 1 Shared proteins between vaccine A and MDBK
cell surface
No. Identified Protein Accession Number MW(kDa)
1 Histone H2B type 1 ENSBTAP00000024155 25
2 40S ribosomal protein S3 ENSBTAP00000003962 27
3 40S ribosomal protein S4 ENSBTAP00000052226 30
4 60S ribosomal protein L7a ENSBTAP00000015358 30
5 Actin, cytoplasmic 2, N-terminally
processed
ENSBTAP00000008132 42
6 Alpha-actinin-4 ENSBTAP00000014894 105




9 Alpha-enolase ENSBTAP00000017839 47
10 Pyruvate kinase ENSBTAP00000044619 61




13 Alpha-2-HS-glycoprotein ENSBTAP00000000673 38
14 MHC class I heavy chain isoform 1 ENSBTAP00000031126 40
15 Heat shock cognate 70 kDa
protein 8
ENSBTAP00000017497 71
16 Hemopexin ENSBTAP00000004635 52
17 ATP synthase subunit alpha,
mitochondrial
ENSBTAP00000003259 60
18 ATP synthase subunit beta,
mitochondrial
ENSBTAP00000017710 56
19 Complement C3 ENSBTAP00000022979 187
20 Complement C4 ENSBTAP00000009019 102
21 Vitamin D-binding protein ENSBTAP00000033386 53
22 Thrombospondin-1 ENSBTAP00000002600 129
23 Alpha-1-acid-glycoprotein ENSBTAP00000022991 23
24 Alpha-1-antiproteinase ENSBTAP00000004927 46
25 Adenylate kinase 2, mitochondrial ENSBTAP00000023406 26
25 proteins could be co-identified in vaccine A and on MDBK cells. Proteins
listed were identified by LC-MS/MS with a probability score that is significant
with p < 0.05 if the confidence score was >30 at a significance threshold for
the Mascot result of p ≤ 0.01. Accession number as listed on Ensembl
database (http://www.ensembl.org).dehydrogenase (GAPDH). Also, the chaperone heat shock
cognate 70 kDa protein 8 (hsc70) and an inhibitor of cys-
teine and serine proteases, endopin-2 [12] belong to this
fraction. Besides, two membrane-bound proteins, namely
sodium/potassium-transporting ATPase subunit alpha-1,
essential for osmoregulation [13], and MHC I heavy chain
isoform 1, which is expressed on all mammalian nucleated
cells [14], were identified (Table 1, proteins 12 and 14).
Further, eight serum-derived proteins were detected
(Table 1, proteins 13, 16 and 19–24). Complement 3 (C3)
and C4 are abundant blood components and members of
complement cascade [15]. Alpha-2-HS-glycoprotein, vita-
min D-binding protein (VDBP), alpha-1-acid-glycoprotein,
and hemopexin represent important transport proteins
[16-19], alpha-1-antiproteinase participates in wound-
healing [20] and thrombospondin-1 (TSP-1) is associated
with platelet aggregation [21]. The protein percentage of
total spectra, the number of unique peptides of the pro-
teins identified, the number of total spectra identified for
respective proteins and the percentage of amino acids
identified in vaccine A are presented in Table 2. According
to these parameters, the most abundant of the proteins
detected concurrently in vaccine A and on MDBK cell
surface was C4 (Table 2, protein 1), while 60S ribosomal
protein L7a and MHC class I heavy chain (Table 2, pro-
teins 24 and 25) were the least abundant.
Discussion
For the first time, we characterized the proteome of two
BVD vaccines and compared their protein content and
concentration in regard to BNP pathogenesis. The inacti-
vated BVD vaccine A contained over 3.5 fold more pro-
teins than the live-attenuated vaccine B and still over
twice as many compared to a meningococcal vaccine,
where 47 proteins were identified by similar proteomic
approaches [22]. Total protein quantity of vaccine A and
MDBK cells was almost equal, underlining our findings
that the protein content of vaccine A and the host cell line
surface resemble each other (Figure 1C and D). This indi-
cates that the vaccine antigens have not or only insuffi-
ciently been purified. Further, the number of individual
proteins was much lower in vaccine B compared to vac-
cine A, which was expected of the live-attenuated vaccine
B and the reason why it was used as a qualitative negative
control. Also, the protein concentrations of both vaccines
differed greatly. Thus, the administered amount of protein
in vaccine A exceeds the one applied when immunizing
with vaccine B according to dosage instructions.
Furthermore, we provided proteomic characterization of
MDBK cell surface. 66% of identified proteins on MDBK
cells were attributed with the Gene Ontology project
terms “plasma membrane”, “cell surface” or “extracellular”,
indicating a high enrichment of proteins already known to
be allocated to the plasma membrane. Although this
Table 2 Abundance of proteins in vaccine A shared with MDBK









1 Complement C4 ENSBTAP00000009019 102 0.150 36 81 30.0
2
Actin, cytoplasmic 2, N-terminally
processed
ENSBTAP00000008132 42 0.120 10 64 45.0
3 Pyruvate kinase ENSBTAP00000044619 61 0.066 17 35 40.0
4 keratin, type II cytoskeletal 8 ENSBTAP00000001108 54 0.057 13 30 31.0
5 Histone H2B type 1 ENSBTAP00000024155 25 0.055 4 29 35.0




ENSBTAP00000037577 36 0.038 8 20 37.0
8 Alpha-1-antiproteinase ENSBTAP00000004927 46 0.032 2 17 7.2
9 Heat shock cognate 70 kDa protein 8 ENSBTAP00000017497 71 0.032 12 17 29.0
10
ATP synthase subunit beta,
mitochondrial
ENSBTAP00000017710 56 0.028 9 15 25.0
11 Alpha-actinin-4 ENSBTAP00000014894 105 0.026 11 14 19.0
12 Alpha-1-acid glycoprotein ENSBTAP00000022991 23 0.021 5 11 31.0
13 Vitamin D-binding protein ENSBTAP00000033386 53 0.019 2 10 7.0
14 Adenylate kinase 2, mitochondrial ENSBTAP00000023406 26 0.017 7 9 42.0
15 40S ribosomal protein S3 ENSBTAP00000003962 27 0.013 3 7 15.0
16 Alpha-enolase ENSBTAP00000017839 47 0.013 5 7 18.0
17
ATP synthase subunit alpha,
mitochondrial
ENSBTAP00000010806 60 0.011 4 6 12.0
18 Endopin 2 ENSBTAP00000011576 47 0.009 3 5 13.0
19 Hemopexin ENSBTAP00000004635 52 0.009 3 5 12.0




ENSBTAP00000001646 113 0.008 3 4 3.3
22 40S ribosomal protein S4 ENSBTAP00000052226 30 0.006 3 3 12.0
23 Complement C3 ENSBTAP00000022979 187 0.006 3 3 4.9
24 60S ribosomal protein L7a ENSBTAP00000015358 30 0.004 2 2 13.0
25 MHC class I heavy chain isoform 1 ENSBTAP00000031126 40 0.004 2 2 6.4
Proteins identified concurrently in vaccine A and on MDBK cell surface by LC-MS/MS are shown in the order of the protein percentage of total spectra, reflecting
their abundance in vaccine A, from lowest to highest concentration. Accession number as listed on Ensembl database (http://www.ensembl.org). Proteins listed
were identified with a probability score that is significant with p < 0.05 if the confidence score was >30 at a significance threshold for the Mascot result of p ≤
0.01. total spectra (%): percentage of total spectra assigned to respective protein. unique peptide count: number of unique peptides for the identified protein. total
spectra: number of total spectra assigned to the identified protein. coverage (%): percentage of total amino acid sequence covered with the identified peptides.
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most membrane-associated fraction enrichment methods,
as one third of these identified proteins are currently not
attributed as cell surface proteins, it could on the other
hand also point out that several proteins might be add-
itionally expressed on the cell surface, but that their pres-
ence on this location has not yet been described. One
prominent example is ATP Synthase, an ubiquitous pro-
tein of the oxidative phosphorylation pathway which was
considered to be an exclusively mitochondrial protein for
decades, but was discovered recently on the cell surface of
a great variety of cell types [23]. MDBK cells are often
used as culture system for growing attenuated viruses invaccine production [24], e.g. BVDV [9]. Proteins detected
in all preparations or overlapping in one vaccine and
MDBK cells indicate an impurity of the vaccines with
homologous proteins due to manufacturing processes.
Proteins present in both vaccines suggest a vaccine spe-
cific role, possibly as adjuvants. Calreticulin, for instance,
which was detected in both vaccines, aids in antigen pre-
sentation promoting antigen contact to MHC I [25]. This
immune enhancing property constitutes its use as com-
pound of vaccines, especially tumor vaccines [25].
By characterizing the host cell line used in manufacturing
vaccine A, vaccine A itself and the qualitative negative
control vaccine B proteomically, we were able to narrow
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interesting candidates which might be involved in patho-
genesis of BNP. Here we discuss proteins that we believe
deserve further evaluation because they offer interesting
properties such as an association with clotting, being pre-
viously reported to be involved in immune diseases that
show symptoms similar to the ones seen in BNP or a loca-
tion on cell types affected in BNP pathogenesis. The rapid
decrease in the number of platelets and leukocytes in the
circulating blood within the first few hours after colos-
trum intake is most likely directly antibody-mediated and
probably not due to bone marrow depletion. Whereas the
haematopoietic progenitor cells are compromised in their
ability to form colonies as early as 24 hours after uptake of
colostral antibodies, the decrease of haematopoietic pro-
genitor cells develops over a longer period of time [6].
Thus, we suspect the antigen or antigens to be located on
PBL, platelets and, in regard to the bone marrow deple-
tion, also on haematopoietic progenitor cells of the mye-
loid and lymphoid lineages.
Interestingly, Pfizer used a new potent adjuvant in vac-
cine A, containing immunostimulating complexes. These
structures envelop the antigen enhancing its uptake into
immune-modulatory cells [26]. The saponin mixture Quil
A is part of these complexes. Its use in human vaccines
was restricted based on its high toxicity and haemolytic
effect [27], until introduction of respective complexes
reduced these effects [28]. Further, the adjuvant also con-
tains drakeol 5, a regular mineral oil, which is often used
in veterinary vaccine production and helps stabilize the
emulsion of vaccine components. Since it cannot be meta-
bolized, it maintains a slow release of antigen and remains
in the injected tissue as an oil pool or depot. It is also
known to lead to a prolonged irritation at the injection
site, thus reflecting the possible side effects of the vaccine
according to the instruction leaflet [29].
The adjuvant is believed to have potentiated reactions to
alloantigens present in vaccine A [9]. To avoid a false nega-
tive selection of our candidate proteins, we chose a live-
attenuated vaccine as negative control. On the one hand,
these vaccines generally contain less protein than inacti-
vated vaccines. Acquiring another BVD vaccine with a high
protein variety, as other inactivated vaccines predictably
would show, would have beared the risk of ruling out valu-
able candidate proteins that might only lead to antibody
production due to the effect of the new adjuvant used in
vaccine A. On the other hand, a live-attenuated vaccine
more likely provides proteins that are only present due to
certain technical limitations of manufacturing processes in
vaccine production.
Pfizer withdrew the registration of vaccine A in Eur-
ope in June 2010 (in Germany even two months earlier,
in April 2010). It took another 14 months until vaccine
A was drawn from the market in New Zealand inAugust 2011, right after the first case was reported there.
It is worth mentioning that there is a close correlation of
the time period when vaccine A was brought to market
in Europe in 2004, with cases of haemorrhagic diatheses
occurring cumulatively in 2007, and it being available for
vaccination in New Zealand in May 2008 where also,
three years later, the first diagnosed case of BNP oc-
curred in August 2011.
Analysing the MDBK cell surface proteome (see Additional
file 1), we detected several interesting BNP alloantigen
candidates, such as integrin alpha-IIB (CD41) and von
Willebrand factor, that have essential functions in clotting
[30,31]. Although they did not appear in vaccine A, we
hypothesized that, since the oily formulation of the vac-
cine made it difficult to handle it technically [5], the anti-
gen might have been undetectable by LC-MS/MS. Thus,
we tried to validate CD41 in vaccine A by Western blot
analysis with an antibody directed against human CD41
protein (data not shown) since this was the only available
commercial antibody at this point of time, but did not
succeed in verifying our hypothesis.
Proteins identified in vaccine A and MDBK cells
(Tables 1 and 2) demonstrate a clear difference in com-
position of vaccine A and B. This group most likely con-
tains candidate proteins capable of triggering production
of alloantibodies in BNP pathogenesis.
Several of these proteins are common cellular compo-
nents (Table 1, proteins 1–12, 14, 15, 17, 18 and 25). For
instance, GAPDH contributes to cellular energy supply
and is considered a housekeeping protein [32]. Occur-
rence of these MDBK cell associated proteins in vaccine
A (and lack of these in vaccine B) confirm high amount
of cellular debris in vaccine A.
Previous studies described vaccine A being contami-
nated with MHC I, which was also present on MDBK cells
and supposedly induced alloreactive antibodies in BNP
dams [4,5]. Although we detected MHC I in both prepara-
tions (Table 1, protein 14 and Table 2, protein 25), we do
not support the hypothesis that MHC I alloantibodies
cause BNP pathogenesis. We could show by immuno-
logical characterization that BNP alloantibodies have an-
other binding pattern than MHC I expression [3]. There
was a difference in alloantibody binding to different
lymphocyte subsets whereas MHC I is evenly expressed
on all lymphocytes [14]. Also, MHC I was the least abun-
dant protein according to the protein percentage of spec-
tral counts in our LC-MS/MS results (Table 2, protein 25).
Further, human MHC I (HLA I) alloantibodies contribute
to transfusion-related acute lung injury (TRALI), a fre-
quent complication in transfusion medicine [33]. Affected
patients develop acute lung edema within six hours of
transfusion, caused by administration of a great amount of
antibodies from donor blood directly into the recipient’s
circulation. This contrasts to BNP, where calves suffer
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though MHC I antibodies were the most frequent alloanti-
bodies (73%) detected in TRALI, they were only weak
triggers and did not cause any fatal case [34]. Still, not all
important transfusion alloantigens are detected for
humans. This was recently shown by Greinacher et al.
who identified a biallelic polymorphism in human neutro-
phile antigen 3a (HNA-3a) as alloantigen in TRALI, result-
ing from a single-nucleotide exchange in the choline
transporter-like protein [33]. HNA-3a is a more potent
alloantigen causing a more severe and fatal course of
TRALI. Identification of this alloantigen was technically
challenging and covered by prominent anti MHC I im-
mune reaction of respective patients. This could also be
the case in BNP, therefore investigation of involved alloan-
tigens continues until pathogenesis induction is proven by
a monospecific antibody.
Interestingly, we identified several proteins that were pre-
viously described as targets in auto- or alloimmune-
mediated diseases. Alpha-enolase (Table 1, protein 9 and
Table 2, protein 16), a glycolytic enzyme and plasminogen-
binding protein on leukocytes [35], is an autoantigen in
rheumatoid arthritis [36] and Behcet’s disease [37]. Hsc70
(Table 1, protein 15 and Table 2, protein 9) acts as
chaperone of proteins to other chaperones or membranes
and takes part in cellular thermo tolerance [38]. Antibodies
against heat shock proteins were detectable in many auto-
immune diseases, e.g. myasthenia gravis [39]. ATP synthase
(Table 1, proteins 17 and 18 and Table 2, proteins 10 and
17) catalyzes ATP from ADP at the mitochondrial mem-
brane and is present on surface of various cells, including
endothelial cells, where it is an autoantigen in immune-
mediated vasculitides [40]. Although C3 and C4 (Table 1,
proteins 19 and 20 and Table 2, proteins 1 and 23) play a
significant role in the innate immune system [15] a mouse
model demonstrated that deficiency in C3 can be compen-
sated by thrombin [41] and a genetically determined defi-
ciency of C4 increases the risk for developing systemic
lupus erythematosus [42]. Alloantibodies directed against
this group of proteins, however, seem unlikely to be involved
in BNP pathogenesis as their functions and the immune-
mediated diseases do not correlate with bleeding disorders.
In addition, we were able to detect candidate proteins
directly affecting cell types reported as BNP targets, namely
platelets, monocytes, granulocytes, B- and T-cells [3].
Vitamin D binding protein (Table 1, protein 21 and
Table 2, protein 13) acts as transport protein for vitamin
D in plasma, and is present on human neutrophils, B-cells
and a subset of T-cells, enhancing C5a chemotaxis of
macrophages and neutrophils [43]. Alloantibodies against
these cells could explain several symptoms of BNP, e.g.
lymphocytopenia and neutropenia [1].
A further interesting BNP alloantigen candidate was
thrombospondin-1 (TSP-1; Table 1, protein 22 and Table 2,protein 6), a protein secreted by and bound on surface of
various cells including endothelial cells, monocytes,
macrophages, and platelets [44]. It is an important inter-
actor of coagulation proteins such as fibrinogen, fibrin,
integrins and neutrophil elastase. It activates leukocytes,
inhibits T-cell effectors and directly induces T-cell apop-
tosis [44]. Further, it promotes T-cell adhesion and chemo-
taxis [44]. TSP-1 null mice showed increased bleeding and
colonic inflammation in acute induced colitis compared to
controls [44]. Therefore, TSP-1 merits further exploration
as possible BNP alloantigen.
Alpha-1-acid-glycoprotein (Table 1, protein 23 and
Table 2, protein 12) was detected, a plasma protein with
many immune-modulatory functions, e.g. expression of
anti-inflammatory cytokines by macrophages, decreasing
chemotaxis of neutrophils and inhibiting proliferation of
lymphocytes [19]. It is also synthesized during granulocyte
differentiation and stored in granules, but can further be
produced at inflammation sites, e.g. by endothelial cells
and activated macrophages, or transported to affected tis-
sues by defensive cells, for instance neutrophils [19]. This
protein has several functions in BNP pathogenesis asso-
ciated pathways, therefore, alloantibodies against alpha-1-
acid-glycoprotein might potentially play an important role
in development of BNP.
An additional interesting candidate was alpha-1-
antiproteinase (Table 1, protein 24 and Table 2, protein 8).
It plays an important role in wound-healing [20], inhibit-
ing plasmin and activating plasminogen and thrombin,
and also inhibits haematopoietic stem cell mobilization in
bone marrow [45]. Further, in vitro studies showed an
increase of lipopolysaccharide-mediated macrophage acti-
vation and anti-inflammatory effects on B-cells, demon-
strating an additional role in immune regulation [46].
Whereas inactivating mutations and deficiencies of alpha-
1-antiproteinase only resulted in elastase-induced tissue
damage, such as skin hyperextensibility [47], chronic
obstructive pulmonary disease and liver disease [46] in
humans, but not in bleeding disorders, the Pittsburgh
mutation of alpha-1-antiproteinase results in a fatal haem-
orrhagic diathesis due to greatly enhanced protease-
inhibitory effects on thrombin, thus blocking the coagula-
tion cascade [46]. These functions of alpha-1-antiproteinase
make it an interesting BNP alloantigen candidate. We will
therefore further examine an involvement of anti-alpha-1
-antiproteinase immune reactions in BNP pathogenesis.
Additionally, we identified adenylate kinase 2 (AK 2;
Table 1, protein 25 and Table 2, protein 14) in vaccine A
and MDBK cells. AK 2 is present in platelets, CD14+,
CD19+, CD3+, CD56+, CD66b+ cells and in mononuclear
cells obtained from bone marrow [48]. AK 2 mutations
cause reticular dysgenesis, the most severe combined im-
munodeficiency in humans [48]. In reticular dysgenesis,
mononuclear cells decrease in bone marrow, thus blocking
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duces similar aberrations in the haemogram and bone mar-
row as described for BNP [2], resulting in monocytopenia,
neutropenia, and lymphopenia combined with normal
erythrocyte count and thrombocytopenia in some cases
[49]. AK 2 knock-down in zebrafish caused similar altera-
tions in leukocyte development, emphasizing the high level
of conservation of AK 2 in different species [48]. Further,
loss of AK 2 does neither interfere with development of
immature hematopoietic cells nor erythropoiesis, but with
lymphocyte development which in this case cannot be
compensated by AK 1 due to lower or absent expression in
respective cell types [48]. Affected cell subsets, the asso-
ciation to bone marrow and alterations in haemogram
closely resemble alterations seen in BNP [2]. Thus, we con-
sider AK 2 the most promising candidate in this study.
However, further investigations have to aim at validating
its role in BNP pathogenesis.
Conclusions
We provide the first characterization of MDBK cell sur-
face proteome and the proteomes of two BVD vaccines.
BNP associated BVD vaccine A contained 159 proteins in
comparison to BVD vaccine B (43 proteins, not BNP-
related). The great overlap of cellular and serum-derived
components confirmed contamination of the BNP related
vaccine A with proteins from MDBK cell line used for
vaccine production. Several interesting BNP candidate
alloantigens could be detected within the overlap of pro-
teins present in BNP related vaccine A and on MDBK cell
surface. VDBP, TSP-1, alpha-1-acid-glycoprotein, alpha-1-
antiproteinase, and AK 2 associate with coagulation and
show a distribution resembling the affected tissues and
cell populations in BNP. Alloantibodies against these pro-
teins could play an important role in BNP pathogenesis




MDBK cells (kindly provided by Falko Steinbach, Veterinary
Laboratories Agency - Weybridge New Haw, Addlestone,
Great Britain) were cultivated in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal calf serum
(FCS) and 1% penicillin/streptomycin. Cells were main-
tained at 37°C and 5% CO2. For protein expression analysis
by mass spectrometry, cells were harvested with Trypsin/
EDTA (Biochrom, Berlin, Germany), washed twice with
cold phosphate buffered saline, and centrifuged between
washing steps at 4°C, 500 × g for 10 minutes (min). Prior
to cell lysis, plasma membrane proteins of 2 × 106 cells
were labelled with 77.4 μg biotin. After 30 min rotation at
4°C and two centrifugation steps at 2800 × g and 16000 ×
g for 10 min each at 4°C, cells were lysed with 1% NonidetP-40, 150 mM NaCl, 1× Roche Complete Protease
Inhibitor, EDTA-free; 5 mM 2-Iodacetamide in 10 mM
Tris–HCl pH 7.6 and biotinylated cell surface proteins
were captured using Streptavidin-beads (IBA, Goettingen,
Germany). After extensive washing to remove unspecifi-
cally bound proteins, captured proteins were cleaved
through digesting beads overnight with trypsin (Promega,
Mannheim, Germany) followed by incubation with glycerol-
free PNGase F (New England Biolabs, Frankfurt/Main,
Germany) at 37°C. Peptides were purified and concen-
trated using Pierce PepClean C18 spin columns (Thermo
Fisher Scientific, Bonn, Germany) according to manufac-
turer’s protocol and subjected to analysis by liquid-
chromatography mass spectrometry/mass spectrometry
(LC-MS/MS).
SDS-PAGE
After overnight precipitation of proteins from vaccine A
with acetone at −20°C, the resulting pellet was resolubi-
lized and both vaccines were resolved by 12% SDS-PAGE
(sodium dodecyl sulfate polyacrylamide gel), followed by
staining with Coomassie Brilliant Blue. After proteolysis
with trypsin, samples were subjected to analysis by LC-
MS/MS.
MDBK cells were solubilized with lysis buffer (9 M urea,
2 M thiourea, 1% DTT, 4% CHAPS, and 2.5 mM each of
EGTA and EDTA) and protein content of both vaccines
and the cell lysate was quantified with Bradford assay
(Sigma-Aldrich, Deisenhofen, Germany).
Vaccine proteins and MDBK cell proteins were resolved
by 10% SDS-PAGE, applying PageRuler Prestained Protein
Ladder (Thermo Fisher) as reference marker. Gels were
stained with silver and colloidal Coomassie [50] for a first
comparison of protein content in vaccine A (related to
BNP alloantibody generation [5]), vaccine B (unrelated to
BNP alloantibody production) and MDBK cells.
Mass spectrometry
LC-MS/MS analysis was performed as described before
[51,52]. Briefly, peptides were separated on a reversed
phase chromatography column (PepMap, 15 cm x 75 μm
ID, 3 μm/100A pore size, LC Packings) operated on a
nano-HPLC apparatus (Ultimate 3000, Dionex, Idstein,
Germany). The nano-HPLC was connected to a linear
quadrupole ion trap-Orbitrap (LTQ Orbitrap XL) mass
spectrometer (Thermo Fisher). The mass spectrometer
was operated in the data-dependent mode to automatic-
ally switch between Orbitrap-MS and LTQ-MS/MS acqui-
sition. Survey full scan MS spectra (from m/z 300 to
1500) were acquired in the Orbitrap resolution R = 60,000
at m/z 400. Up to ten most intense ions were in parallel
selected for fragmentation on the linear ion trap using
collision induced dissociation at a target value of 100,000
ions and subsequently dynamically excluded for 30 s.
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ware as Mascot Generic file (mgf) and used for peptide
identification using Mascot (Matrix Science, London, UK;
http://www.matrixscience.com), the Uniprot database
(http://www.uniprot.org) restricted to mammalian entries,
the Ensembl bovine database (http://www.ensembl.org) in
particular, and the EMBL-Bank (http://www.ebi.ac.uk/
embl/) for nucleotide sequences. A protein was considered
as identified, if the confidence score was higher than 30 at
a significance threshold for the Mascot result of p ≤ 0.01.
Gene ontology project term classification of MDBK cell
surface proteins
Proteins identified on MDBK cell surface by LC-MS/MS
were used for annotation of GO terms “cellular compo-
nent”. GO terms were retrieved from the Ensembl data-
base and AmiGO (AmiGO version 1.8; GO database
release 2012-12-08; http://amigo.geneontology.org), either
directly from the entries in the bovine database or by
searching orthologes in human, mouse or rat.
Additional file
Additional file 1: Summary of proteins identified in vaccine A,
vaccine B and on MDBK cell surface In total, 310 proteins were
identified in vaccine A, vaccine B and on MDBK cell surface. A:
Number of protein in list order. B: Protein name. C: Accession number as
listed on Ensembl database (http://www.ensembl.org) or in EMBL
Database (http://www.ebi.ac.uk/embl/), respectively. D: Molecular weight
in kDa. x indicates that the protein was identified in the according
preparation. Proteins listed were identified by LC-MS/MS with a
probability score that is significant with p < 0.05 if the confidence score
was >30 at a significance threshold for the Mascot result of p ≤ 0.01.
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